Molecular classification of breast cancers based on genomic profiling can differentiate Luminal cancers (mostly impacted by endocrine pathways) from HER-2-enriched and Basal-like cancers in terms of therapeutic response and prognosis [13]. Here, ERBB2 is linked to cancer.